Printer Friendly

PregLem inks in-licensing deal with Merck Serono for Bentamapimod.

M2 PHARMA-August 11, 2010-PregLem inks in-licensing deal with Merck Serono for Bentamapimod(C)2010 M2 COMMUNICATIONS

11 August 2010 - Swiss specialty biopharmaceutical company PregLem said today it has signed a worldwide, exclusive in-licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor (JNK-I AS602801) with Merck Serono,a division of Merck KGaA (ETR: MRK).

PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

JNK-I (PGL5) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative adhesions. Preclinical data show that the compound is an effective anti-inflammatory with anti-fibrotic properties, PregLem added.

PregLem said it plans to initiate a clinical proof of concept study and a Phase II study during 2011 for the prevention of post-surgical abdominal adhesions and/or endometriosis in patients with tubal ligation or comparable effective contraception.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 11, 2010
Words:178
Previous Article:Onset Medical gets FDA marketing clearance for additional size applications for SoloPath Endovascular Access Catheter.
Next Article:Genzyme warns its production problems may last longer than expected.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters